Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, Rebecca Asher, Dominique Berton, Laura Vidal, Patricia Pautier, Jonathan A. Ledermann, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Nicoletta Colombo, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alison Freimund, Chee Khoon Lee, Éric Pujade-Lauraine